SUMMARY Since sulphonamides are no longer predictably effective in the treatment of chancroid the combination of trimethoprim-sulphamethoxazole (TMP-SMX) was evaluated to identify other effective regimens. One hundred and nine patients with genital ulcers (75 men and 34 women) seen at the Special Treatment Clinic in Nairobi, Kenya, were randomly assigned to treatment with a seven day course of either sulphamethoxazole 1000 mg twice daily or trimethoprim (160 mg)-sulphamethoxazole (800 mg) (TMP-SMX) twice daily. Haemophilus ducreyi was isolated from the ulcer in 57 patients (33 men and 24 women). 16 patients were subsequently diagnosed serologically as having syphilis. No aetiological diagnosis was made in 40 patients. Treatment with sulphamethoxazole failed in five of 21 (24%) culture positive patients who were available for evaluation after seven days, whereas all 19 of such patients who were treated with TMP-SMX responded to treatment. Of the 21 isolates available for susceptibility testing, all were susceptible to trimethoprim alone (MIC <0 5 mg/l) and three were resistant to sulphonamides, all three containing a 4 9 megadalton (Mdal) plasmid. Two of the three patients from whom these isolates had been obtained were treated with sulphamethoxazole and both were clinical and bacteriological failures. Five of six patients with sulphonamide-susceptible H ducreyi responded to treatment with sulphamethoxazole. Failure of sulphonamides to eradicate H ducreyi in some patients with chancroid is associated with the presence of a sulphonamide resistant plasmid. In regions where this plasmid is present in H ducreyi TMP-SMX is the preferred treatment for chancroid.
Introduction
For more than four decades sulphonamides have been the treatment of choice for patients with chancroid. Their effectiveness against Haemophilus ducreyi has been widely reported both in vitro,1-3 and in therapeutic studies.4-9 Some patients with chancroid do not, however, respond to sulphonamide treatment and not all patients are able to tolerate sulphonamides. [9] [10] [11] [12] Several other antibiotics which have been shown to be therapeutically useful include: penicillin,'3 the aminoglycosides,12 14 15 cephalothin,"I chloramphenicol, '3 16 and the tetracyclines.9 16 17 Of these, only the tetracyclines have been widely used. In vitro resistance of H ducreyi and clinical failures have, however, been reported from several countries. [9] [10] [11] [12] In a previous study we showed that a sulphonamide-trimethoprim combination was an effective cure for chancroid.'8 Numerous isolates of H ducreyi from Canada, the United States, Europe, and Africa have been tested in our laboratory and found to be susceptible in vitro to trimethoprim-sulphamethoxazole (TMP-SMX). While investigating doxycycline Stamps noted that eight tablets of TMP-SMX (equivalent to 640 mg of trimethoprim and 3 e 2 g of sulfamethoxazole) given as a single dose offered promise in the treatment of genital ulcer disease in Zimbabwe. '7 from Rotterdam suggests that the combination is uniformly effective both in vivo and in vitro against H ducreyi. 19 On the basis of this evidence we undertook a controlled double-blind study to compare All patients were requested to return after 2, 7, 10, 14, and 28 days. At each visit the patient's subjective response to treatment was ascertained and lesions were re-examined for clinical response to treatment. All unhealed ulcers were recultured for H ducreyi. Serology tests were repeated on days 7 and 28. TREATMENT Patients were randomly assigned in a double-blind fashion to receive for seven days either sulphamethoxazole 1000 mg by mouth twice daily or TMP-SMX, 160 mg trimethroprim and 800 mg sulphamethoxazole, by mouth twice daily. If the ulcer was showing evidence of healing on day 7 no further medication was prescribed and the patient was requested to return for follow up. If the ulcer had failed clinically, bacteriologically, or both to respond by day 7 the patient was given the alternative drug regimen.
Results
Enrolled in the study were 109 patients (75 men and 34 women) whose ages ranged from 15 to 40 years. H ducreyi was isolated from the ulcer in 57 (52%) cases and these patients (33 men and 24 women) form the basis for the evaluation of treatment. In 16 patients ulcers were diagnosed as being due to syphilis either on the basis of a positive dark field examination (five) or positive serology results, that is to the TPHA test and to the RPR test in a dilution of >1/2. These patients are not considered further in this study, except for four (three of whom were men) who had evidence of both T pallidum and H ducreyi infection. Neisseria gonorrhoeae was the only pathogen isolated from two patients and these together with the 38 (31%) patients in whom no aetiological diagnosis could be made are evaluated separately, although it is probable that the ulcers in some of the patients were due to H ducreyi.
Of the 57 patients with diagnoses of chancroid, 29 initially received sulphamethoxazole and 28 TMP-SMX. Determining antimicrobial susceptibilities of fastidious haemin-requiring organisms like H ducreyi is difficult. The primary problem is that of the culture medium, as media that support the growth of H ducreyi cannot necessarily be used for susceptibility testing. We and other investigators have had particular difficulties with sulphonamide and trimethoprim susceptibility testing. Most media that support growth of H ducreyi contain thymidine, which antagonises the antibacterial activity of trimethoprim, and para-aminobenzoic acid (PABA), which competes with the sulphonamides. The medium used in this study appeared to overcome this problem with horse blood providing haemin (haemoglobin) and thymidine phosphorylase, as we knew from previous studies that glucose, glutamine, and cysteine and a source of haemin are necessary for the growth of H ducreyi. Because the organisms are fastidious, however, about one quarter of all isolates would not grow on our susceptibility medium.
The correlation between results of antimicrobial susceptibility testing and clinical and bacteriological response to treatment suggests that the method is valid. Three strains of H ducreyi with MICs greater than 512 mg/l of sulphamethoxazole contained the 4 9 Mdal sulphonamide resistant plasmid and sulphamethoxazole was ineffective in the treatment of these patients. In addition, the MICs of the combination of TMP-SMX were higher in these patients than in patients with sulphonamide susceptible isolates of H ducreyi. Fortunately, all isolates were uniformly susceptible to TMP. Strains which lacked the sulphonamide resistant plasmid had uniformly low MICs (<2-0 mg/l) to sulphamethoxazole and, with one exception, patients with these organisms responded well to treatment with this drug. There is no obvious explanation for the one treatment failure in a man infected with a sulphonamide susceptible organism. His ulcer was severe as were many others and we have no evidence of poor compliance.
The woman whose culture negative ulcer responded to sulphamethoxazole treatment, but whose bubo persisted and from which was isolated H ducreyi containing the 4-9 Mdal plasmid, poses some interesting questions. Was she infected with two strains of H ducreyi? Did an originally susceptible organism acquire a resistant plasmid during the period of infection?
We were surprised that ulcers in women healed more quickly than those in men. It did not appear that women sought treatment when ulcers were less severe or of shorter duration. Although the mean time to healing of ulcers in men treated with sulphamethoxazole appeared longer than for those treated with TMP-SMX, with one exception the ulcers in patients with proved sulphonamide susceptible H ducreyi who were treated with sulphamethoxazole resolved in 10 days. Both drugs were equally effective in women.
Several questions require further investigation. Is trimethoprim alone as effective as the combination, particularly in patients with sulphonamide resistant H ducreyi infections? What is the optimum duration of treatment? Although the Centers for Disease Control recommend that treatment should be continued for a minimum of 10 days and until ulcers, lymph nodes, or both have healed, there is no evidence that shorter regimens may not be equally effective. In all patients with H ducreyi infections in this study who were ultimately cured without further treatment, the ulcer was culture negative on day three and remained culture negative even in patients in whom time to healing was prolonged. Would shorter treatment time be equally effective in eradicating H ducreyi and curing clinical chancroid?
The level of trimethoprim in the combination required to prevent growth was identical to the MIC of trimethoprim alone for the three plasmid containing sulphonamide resistant isolates. In other words, there was no evidence of synergy for these strains. In contrast, for sulphonamide susceptible strains of H ducreyi the MIC of trimethoprim or sulphamethoxazole was either two, four, or eight times greater alone than when combined. True synergy was apparent for most strains. The clinical importance of this antibacterial synergy requires further study. 
